| Zhang, Xing |
NCT04859465: Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable Angiosarcoma |
|
|
| Recruiting | 2 | 69 | RoW | Abraxane combined with liposomal doxorubicin | Sun Yat-sen University | Angiosarcoma Metastatic | 05/24 | 11/24 | | |
NCT04012827: Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma |
|
|
| Recruiting | 2 | 108 | RoW | Apatinib Mesylate, doxorubicin, ifosfamide, Apatinib | Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd. | Soft Tissue Sarcoma | 06/23 | 12/23 | | |
| Recruiting | 2 | 200 | RoW | Toripalimab Combined With CAV/IE chemotherapy, CAV/IE alternate chemotherapy | Sun Yat-sen University | Soft Tissue Sarcoma | 01/25 | 06/26 | | |
NCT05106777: Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 47 | RoW | Surufatinib, HMPL-012 | Sun Yat-sen University | Sarcoma | 12/23 | 12/23 | | |
NCT03890068: Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 48 | RoW | Anlotinib Hydrochloride, Anlotinib | Sun Yat-sen University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Soft Tissue Sarcoma | 12/23 | 05/24 | | |
| Recruiting | 2 | 74 | RoW | chidamide and toripalimab | Sun Yat-sen University | Sarcoma | 12/23 | 12/24 | | |
NCT04589754: Adriamycin and Ifosfamide Combined With Sintilimab |
|
|
| Recruiting | 2 | 176 | RoW | Sintilimab plus chemotherapy, Adriamycin-based chemotherapy | Sun Yat-sen University | Soft Tissue Sarcoma | 12/25 | 07/26 | | |
NCT05497843: Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS) |
|
|
| Active, not recruiting | 2 | 40 | RoW | Chiauranib, CS2164 | Chipscreen Biosciences, Ltd. | Soft Tissue Sarcoma | 12/24 | 12/24 | | |
NCT06277154: MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma |
|
|
| Not yet recruiting | 2 | 148 | RoW | MASCT-I, Doxorubicin, Doxorubicin hydrochloride for Injection, Ifosfamide, Ifosfamide for Injection | HRYZ Biotech Co. | Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma, Undifferentiated Pleomorphic Sarcoma, Epithelioid Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Fibrosarcoma, Pleomorphic Rhabdomyosarcoma, Endometrial Stromal Sarcoma, Desmoplastic Small Round Cell Tumor | 02/26 | 02/27 | | |
NCT04172805: Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma |
|
|
| Recruiting | 2 | 70 | RoW | anlotinib and toripalimab, Anlotinib Hydrochloride | Sun Yat-sen University | Sarcoma,Soft Tissue | 03/24 | 05/24 | | |
RAFAS-001, NCT05894018: Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 32 | RoW | Fluzoparib, Radioactive particle implantation | Fujun Zhang | Sarcoma,Soft Tissue, Brachytherapy, Poly(ADP-ribose) Polymerase Inhibitors | 06/24 | 12/24 | | |
NCT05542433: Phase II Study of Chiauranib Capsule in Advanced or Unresectable Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 30 | RoW | Chiauranib, Chiauranib Capsules | Sun Yat-sen University, Shenzhen Chipscreen Biosciences Co.Ltd | Soft Tissue Sarcoma | 08/24 | 08/24 | | |
NCT05549921: Phase II Study of TAEST16001 in Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 70 | RoW | NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy) | Sun Yat-sen University, Guangdong Xiangxue Precision Medical Technology Co., Ltd. | Soft Tissue Sarcoma | 09/24 | 09/24 | | |
| Recruiting | 2 | 170 | RoW | HS-20093 | Hansoh BioMedical R&D Company | Osteosarcoma, Sarcoma | 12/25 | 12/27 | | |
NCT04785196: APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 95 | RoW | APG-115, Toripalimab | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Liposarcoma, Advanced Solid Tumor | 04/26 | 01/27 | | |
NCT04318964: TAEST16001 in the Treatment of Soft Tissue Sarcoma |
|
|
| Active, not recruiting | 1 | 12 | RoW | TAEST16001 cells | Sun Yat-sen University, Guangdong Xiangxue Precision Medical Technology Co., Ltd. | Soft Tissue Sarcoma | 04/22 | 05/24 | | |
NCT03462316: NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma |
|
|
| Active, not recruiting | 1 | 20 | RoW | NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy） | Sun Yat-sen University, Guangdong Xiangxue Precision Medical Technology Co., Ltd. | Bone Sarcoma, Soft Tissue Sarcoma | 02/24 | 05/24 | | |
TQB2252-I-01, NCT06649656: A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors |
|
|
| Not yet recruiting | 1 | 100 | RoW | TQB2252 injection | Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. | Advanced Cancers | 11/26 | 12/26 | | |
